SAN FRANCISCO and SUZHOU, China, Jan. 15, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic,...
Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent Receives NMPA Breakthrough Therapy Designation for IBI343 (Anti-CLDN18.2 ADC) as Monotherapy for Advanced Pancreatic Cancer )
Also on site :
- Global March to Gaza activists report delays, deportations at Cairo Airport
- Egypt sets strict protocols for Gaza border access amid the Soumoud Convoy arrival
- She helped build Disney’s theme park database. Now Sheila Jordan is leading a $38.5 billion Fortune 500 giant’s digital transformation efforts